Intersex effect of lamotrigine on the pharmacokinetic parameters of CDRI-97/78, a novel trioxane antimalarial compound, in rats

Arzneimittel-Forschung/Drug Research

Volumn 62, Issue 6, 2012, Pages 274-279

  Kushwaha, H N ^a   Gautam, N ^a   Misra, A ^a   Singh, B ^a   Kumar, S ^a   Siddiqui, H H ^b   Singh, S K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b INTEGRAL UNIVERSITY   (India)

Author keywords

antimalarial; drug interaction; lamotrigine; LC MS MS; metabolite 97 63; pharmacokinetics

Indexed keywords

1,2,4 TRIOXANE DERIVATIVE; ANTIMALARIAL AGENT; CDRI 9763; CDRI 9778; LAMOTRIGINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG INTERACTION; FEMALE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SEX DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTICONVULSANTS; ANTIMALARIALS; AREA UNDER CURVE; BICYCLO COMPOUNDS, HETEROCYCLIC; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; FEMALE; HALF-LIFE; INDICATORS AND REAGENTS; MALE; MASS SPECTROMETRY; RATS; RATS, SPRAGUE-DAWLEY; SEX CHARACTERISTICS; TANDEM MASS SPECTROMETRY; TRIAZINES;

EID: 84862837092     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0032-1306317     Document Type: Article

References (28)

1. Sperber K, Chiang G, Chen H et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther: 1997; 19 913 923 (Pubitemid 27508927)
2. Yuen AW C, Land G, Weatherley B. Sodium valproate inhibits lamotrigine metabolism. Br J Clin Pharmacol: 1992; 33 511 513
3. Besag F M, Berry D J, Pool F. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia: 1998; 39 183 187 (Pubitemid 28074354)
4. Majkowski J. Antiepileptic and nonantiepileptic drug interactions. Epileptologia: 1998; 6 55 73
5. Sander J W, Perucca E. Epilepsy and comorbidity: infections and antimicrobials usage in relation to epilepsy management. Acta. Neurol Scand: 2003; 108 180 16 22
6. Gupta S, Thapar M M, Wernsdorfer W H. In vitro interactions of artemisinin with atovaquone, quinine, and mefloquine against Plasmodium falciparum. Antimicrob. Agents Chemother: 2002; 46 1510 1515 (Pubitemid 34415335)
7. Patsalos P N, Duncan J S. Antiepileptic drugs; a review of clinically significant drug interactions. Drug Saf: 1993; 9 156 184 (Pubitemid 23283910)
8. Patsalos P N. Pharmacokinetics and pharmacodynamic interaction; principles and interpretative pitfalls. Epileptologia: 1998; 6 9 19
9. Patsalos P N. Therapeutic drug monitoring in epilepsy: the established and the new antienilentic drugs. Epilepsy Monit: 2002; 6 1 8
10. Brahmankar D M, Jaiswal S B. Biopharmaceutics and pharmacokinetics- A treatise. New Delhi Vallabh Prakashan: 1997
11. Bonate P L, Reith K, Weir S. Drug interactions at the renal level. Implications for drug development. Clin Pharmacokinet: 1998; 34 375 404 (Pubitemid 28192907)
12. Hansten P D. Understanding drug interactions. Sci. Med: 1998; Jan/Feb: 16 25
13. Tanaka E. Clinically important pharmacokinctic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharmacol Ther: 1998; 23 403 416 (Pubitemid 29060690)
14. Lundahi J, Regardh C G, Edgar B et al. Effect of grapefruit juice ingestion - pharmacokineties and haemodynamics of intravenously and orally adminisitered felodipine in healthy men. Eur J Clin Pharmacol: 1997; 52 139 145
15. th edition London The Pharmaceutical Press: 1994; 342
16. nd edition. New York Marcel Dekker Inc: 1995; 335 410
17. Singh R P, Sabarinath S, Gautam N et al. Liquid chromatographic tandem mass spectrometric assay for quantification of 97/78 and its metabolite 97/63: A promising trioxane antimalarial in monkey plasma. J Chromatogr B: 2009; 877 2074 2080
18. Singh R P, Sabarinath S, Gautam N et al. Pharmacokinetic study of the novel, synthetic trioxane antimalarialcompound 97-78 in rats using an LC-MS/MS method for quantification. Arzneimittelforschung: 2011; 61 120 125
19. Shah V P, Midha K K, Findlay JW A et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm Res: 2000; 17 1551 1557 (Pubitemid 32217566)
20. Freireich E J, Gehan E A, Rall D P et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep: 1966; 50 219 244
21. th edition New Delhi Jaypee Brothers Medical Publishers(P) Ltd: 2010
22. Bjornsson T D, Callaghan J T, Einolf H J et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos: 2003; 31 815 832 (Pubitemid 36759050)
23. Huang S M, Lesko L J. Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J Clin Pharmacol: 2004; 44 559 569 (Pubitemid 38668017)
24. Yuan R, Madani S, Wei X X et al. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos: 2002; 30 1311 1319 (Pubitemid 35397032)
25. Davit B, Reynolds K, Yuan R et al. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J Clin Pharmacol: 1999; 39 899 910 (Pubitemid 30644025)
26. Mizuno N, Niwa T, Yotsumoto Y et al. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev: 2003; 55 425 461 (Pubitemid 37013212)
27. Lin J H. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev: 2003; 55 53 81 (Pubitemid 36082882)
28. Tsuji A. Transporter-mediated drug interactions. Drug Metab Pharmacokinet: 2002; 17 253 274